Mode of action of P2Y12 antagonists as inhibitors of platelet function

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thrombosis and Haemostasis

• Publication date

  2010-10-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1160/TH10-07-0482PMID 20941457
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New P2Y12 inhibitors

  2011cited by this paper
• Antiplatelet therapies for the treatment of cardiovascular disease

  2010cited by this paper
• ADP-receptor blockade: A case for personalised pharmacotherapy?

  2010cited by this paper
• Platelet P2Y12 receptor antagonist pharmacokinetics and pharmaco -dynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies

  2010cited by this paper
• A Gi‐independent mechanism mediating Akt phosphorylation in platelets

  2010cited by this paper
• The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function

  2010cited by this paper
• Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

  2010cited by this paper
• New P2Y12 Inhibitors

  2010cited by this paper
• The P2Y12 Antagonists, 2-Methylthioadenosine 5′-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels*

  2009influential reference
• Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation

  2009cited by this paper
• Platelet response heterogeneity in thrombus formation

  2009cited by this paper
• Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL‐8 production in human colonic epithelial cell lines

  2009cited by this paper
• Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis

  2009cited by this paper
• Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• P2 receptors, platelet function and pharmacological implications

  2008cited by this paper
• Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype

  2008influential reference
• The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

  2008cited by this paper
• Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.

  2008cited by this paper
• Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor

  2008cited by this paper
• The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor*

  2008cited by this paper
• Interaction of the active metabolite of prasugrel, R‐138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor

  2008cited by this paper
• DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

  2008cited by this paper
• Abstract 245: AZD6140 Inhibits Adenosine Uptake Into Erythrocytes and Enhances Coronary Blood Flow After Local Ischemia or Intracoronary Adenosine Infusion

  2007cited by this paper
• Prostaglandin E Receptors*

  2007cited by this paper
• The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

  2006cited by this paper
• Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists

  2005cited by this paper
• Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor

  2005cited by this paper
• Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor

  2005cited by this paper
• Central role of the P2Y12 receptor in platelet activation.

  2004cited by this paper
• Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

  2003cited by this paper
• Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin

  2002cited by this paper
• Platelet Activation and Blood Coagulation

  2002cited by this paper
• Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor.

  2001cited by this paper
• Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes

  2001cited by this paper
• A2A adenosine receptors in human peripheral blood cells

  2000cited by this paper
• The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

  2000cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Prostanoid receptors: structures, properties, and functions.

  1999cited by this paper
• Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells

  1998cited by this paper
• Model systems for the study of seven-transmembrane-segment receptors.

  1991cited by this paper
• A cross-sectional study of platelet cyclic AMP in healthy and hypertensive pregnant women.

  1991cited by this paper
• Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets.

  1991cited by this paper
• Measurement of circulating prostacyclin

  1981cited by this paper

• Therapeutic interventions for coronary microvascular obstruction after acute myocardial infarction: Developments and challenges.

  2026cites this paper
• TRAP-Induced Platelet Reactivity Is Inhibited by Omega-3 Fatty Acid-Derived Prostaglandin E3 (PGE3)

  2024cites this paper
• First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction

  2020cites this paper
• The Interplay between Platelets, Infections and Inflammation

  2019cites this paper
• Desialylation of Platelets by Pneumococcal Neuraminidase A Induces ADP-Dependent Platelet Hyperreactivity

  2018cites this paper
• Measurement of platelet aggregation, independently of patient platelet count: a flow‐cytometric approach

  2017cites this paper
• P2Y12 receptor-mediated activation of spinal microglia and p38MAPK pathway contribute to cancer-induced bone pain

  2017cites this paper
• P 2 Y 12 receptor-mediated activation of spinal microglia and p 38 MAPK pathway contribute to cancer-induced bone pain

  2017cites this paper
• Novel strategies for assessing platelet reactivity.

  2017cites this paper
• Algahtani, Mohammad and Heptinstall, Stan (2017) Novel strategies for assessing platelet reactivity. Future

  2017cites this paper
• The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count

  2016cites this paper
• Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes

  2015cites this paper
• Antiplatelet drug interactions with proton pump inhibitors

  2014cites this paper
• Racial Differences in Resistance to P2Y12 Receptor Antagonists in Type 2 Diabetic Subjects

  2014cites this paper
• Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes

  2014cites this paper
• Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk.

  2014cites this paper
• Progress in platelet blockers: the target is the P2Y12 receptor.

  2013cites this paper
• Antiplatelet Agents: Current and Novel

  2013cites this paper
• Ticagrelor: the first novel reversible P2Y12 inhibitor

  2013cites this paper
• Platelet P2Y12 Blockers Confer Direct Postconditioning-Like Protection in Reperfused Rabbit Hearts

  2013cites this paper
• The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

  2012cites this paper
• P2Y12 receptor: platelet thrombus formation and medical interventions

  2012cites this paper
• Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter?

  2012cites this paper
• Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents.

  2012cites this paper
• Anti-platelet therapy: ADP receptor antagonists

  2011cites this paper
• Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y12 Antagonist

  2011cites this paper
• Novel agents for anti-platelet therapy

  2011cites this paper
• Ticagrelor - první reverzibilní inhibitor ADP receptorů typu P2Y12

  2011influential citation
• Ticagrelor

  2011cites this paper
• P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP

  2011cites this paper
• Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy

  2011cites this paper